- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.08. | Vor says drug licensed from RemeGen succeeded in Sjögren's study | ||
| 13.08. | AbbVie to build API plant in Illinois as it steps up US production | ||
| 12.08. | Insmed gains US approval of lung disease drug forecast to be blockbuster | ||
| 12.08. | PureTech launches new biotech built around lung disease drug | ||
| 12.08. | Pfizer looks to expand ADC use after positive bladder cancer data | ||
| 12.08. | Bayer buys into KRAS cancer drug; Novartis immune therapy goes 3 for 3 | ||
| 12.08. | Expedition, a startup searching for drugs from China, cuts its first deal | ||
| 11.08. | IO Biotech sees path forward for skin cancer vaccine despite study setback | ||
| 11.08. | As gene therapy sales sputter, one biotech aims to defy the odds | ||
| 11.08. | Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease | ||
| 11.08. | Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP | ||
| 08.08. | BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal | ||
| 08.08. | Inside AstraZeneca's long-term strategy in lung cancer | ||
| 08.08. | Elevidys sales weaken; Neumora gets into obesity | ||
| 07.08. | Strand raises another $153M to make 'programmable' mRNA drugs | ||
| 07.08. | FDA to start new 'precheck' program to boost US drug production | ||
| 07.08. | Lilly shares fall as obesity pill misses expectations in key trial | ||
| 07.08. | FDA lifts pause on Valneva's chikungunya shot, but adds new limits | ||
| 07.08. | Arvinas, Pfizer reworking partnership on 'Protac' cancer drug | ||
| 07.08. | Iovance cuts staff amid slow sales start for 'TIL' cell therapy | ||
| 06.08. | HHS abandons mRNA vaccine research | ||
| 06.08. | Novo pushes back against obesity drug compounders as competition intensifies | ||
| 06.08. | Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share | ||
| 05.08. | Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO | ||
| 05.08. | Trump threatens up to 250% tariffs on pharma imports |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .